News

Aptuit and BioVersys hope that innovative approaches can address antibiotic resistance in the treatment of serious infections. BioVersys is focused on the development of small molecules interfering with

Ledaga is formulated as a topical, once-daily and colorless gel. MF-CTCL is a rare and potentially life-threatening immune system cancer that forms on the skin. It is the common

Waking up at least two times per night to urinate is known as nocturnal polyuria, overproduction of urine during the night. Noctiva, which is a vasopressin analog, is

CTP-656 is an investigational cystic fibrosis transmembrane conductance regulator (CFTR) potentiator that has the potential to be used as part of future once-daily combination regimens of CFTR modulators

This ground-breaking IND paves the way for bringing a new precision immunotherapy for the treatment of cancers into the clinic this year. ADXS-NEO employs Advaxis’ proprietary Listeria monocytogenes

TG-1101 is a highly potent next generation glycoengineered anti-CD20 monoclonal antibody to ibrutinib monotherapy in high risk CLL. The multicenter GENUINE trial, which evaluated the efficacy and safety of

Ongoing and future trials using the oral formulation of SCY-078 are unaffected by this regulatory action. A meeting with the FDA to discuss these data and to agree

The trial met its primary endpoint of demonstrating a clinically meaningful and a statistically significant increase in overall survival (“OS”), in the intention-to-treat (ITT) population of patients treated

The UK's Competition and Markets Authority (CMA) said both the firms entered into agreements under which Actavis UK incentivised Concordia not to enter the market with its own